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Abstract
Head & Neck Cancer (HNC) represents the sixth most common malignancy worldwide and it is
historically linked to well-known behavioural risk factors, i.e., tobacco smoking and/or the alcohol
consumption. Recently, substantial evidence has been mounting that Human Papillomavirus (HPV)
infection is playing an increasing important role in oral cancer. Because of the attention and clamor
surrounding oral HPV infection and related cancers, as well as the use of HPV prophylactic vaccines,
in this invited perspective the authors raise some questions and review some controversial issues
on HPV infection and its role in HNC, with a particular focus on oral squamous cell carcinoma.
The problematic definition and classification of HNC will be discussed, together with the
characteristics of oral infection with oncogenic HPV types, the frequency of HPV DNA detection
in HNC, the location of HPV-related tumours, the severity and prognosis of HPV-positive HNC,
the diagnosis of oral HPV infection, common routes of oral infection and the likelihood of oro-
genital HPV transmission, the prevention of HPV infection and novel therapeutic approaches.
Background
Taking into consideration the attention and clamor sur-
rounding Human Papilloma Virus (HPV) infection and
related cancers, HPV vaccine controversies, as well as the
recent Nobel Prize awarded to Prof. zur Hausen for his
research on HPV and cervical cancer, authors believe it
opportune, in this invited perspective, to raise various
questions and review some of the most controversial
issues related to HPV and its role in Head & Neck Cancer
(HNC) and particularly in oral squamous cell carcinoma
(OSCC), as well as the diagnosis of oral HPV infection
and its oro-genital transmission.
HNC  represents the sixth most common malignancy
worldwide [1], and it is historically linked to several
behavioural risk factors (i.e., tobacco smoking and/or the
consumption of alcohol). However, this term defines a
heterogeneous group of malignant tumours, involving
several different several sub-sites. The majority of HN
malignancies are squamous cell carcinomas (SCC) and
they originate from the epithelium which lines the upper
aero digestive tract, i.e., the oral cavity, the pharynx and
the larynx. Arising in a multistep process resulting from
the gathering of genetic and epigenetic defects and clonal
spreading out of given cell populations [2], HN malignan-
cies are known as HNSCC.
HPVs are epitheliotropic oncogenic DNA viruses with
more than 120 identified genotypes: the so-called high-
risk (HR) HPV, like HPV 16 and 18, have been definitively
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recognised as being strongly associated with ano-genital
(cervical) cancers. In patients with high-grade neoplasia
and cancer, HR HPV DNA can usually be found integrated
into host DNA. The oncogenic potential of HR HPV is
attributable to its ability to insert specific DNA fragments
(early genes E6 and E7) into the host cellular genome. As
a result of this integration, various key functions of
tumour suppressor factors (the p53 and pRb pathways)
are abrogated, leading to defects in apoptosis, DNA repair
mechanisms, cell cycle regulation and, finally, to cellular
immortalization, thus inducing and maintaining the
malignant phenotype.
The HPV involvement in HN carcinogenesis was first pro-
posed in 1983 by Syrjanen et al. [3] and then supported
by several other authors on the basis of the following evi-
dence: 1) the well-assessed broad epitheliotropism of
HPV; 2) the morphological similarities between oropha-
ryngeal and genital epithelia [4]; 3) the ability of immor-
talizing human oral keratinocytes in vitro [5]; and 4) the
strongly established etiological role of HR HPV in cervical
SCC [6,7].
Whilst occurring in a lower percentage than in cervical
mucosa, HR HPV E6/E7 transcripts and/or viral integra-
tion have also been detected in HNC [8] and, it has, there-
fore, been suggested that HR HPV (mostly HPV 16, 18,
33) are involved in the viral-dependent inactivation of
p53 and Rb. This occurrence also justifies the increased
incidence of HNC and the onset of the tumour in younger
people [9], whether the most common risk factors are
present or not. As well as being associated with genital
and oral mucosa diseases, HPV infection has also been
reported in cases of nasal inverting papilloma, which is
usually a benign tumour but is associated with squamous
cell carcinoma (SCC) in about 10% of cases. Previous
analyses have identified HPV-16 DNA in 32% of inverted
papillomas and 58% papillomas associated with carcino-
mas [10]. More recently, an active role in the malignant
lesion has been suggested for HPV on the basis of the pres-
ence of the HPV oncogene E6 and E7 transcripts, indicat-
ing the integration of the viral genome [11]. However,
further analysis is required to confirm that HPV is not
only a bystander agent.
In addition to these logical statements, it is timely to raise
the following questions and shed light on these controver-
sies:
What is the frequency of HR HPV in HNC?
A very wide range of viral prevalence (0%–100%), in addi-
tion to the presence of HR HPV in oral normal mucosa
[12,13], has been reported in the literature, even if with
limited information regarding the natural history of oral
HPV infection. Specifically relating to HPV 16 and 18, Kre-
imer et al [14] identified these genotypes in 16.0% and
3.9% respectively of 2,642 HNC reviewed in a recent sys-
tematic review of the literature; they calculated an overall
prevalence of HPV in 25% of HNC vs 35.6% in oro-pha-
ryngeal cancer and 23.5% in OSCC. Excluding any ethno-
geographical bias among the patient groups examined,
this wide range depends mainly on two variables: i) the
site of the mucosa examined; and ii) technical issues (or
the HPV molecular assay employed).
What is the precise location of the HPV-related tumour?
A great deal of confusion is created by the use of the
generic term HNC, HNSCC or oral cancer in place of the
specific OSCC, oro-pharyngeal or laryngeal carcinoma. This
issue plays a critical role since specific epithelial areas of
the upper aero-digestive tract (such as the squamous-
columnar junction at the level of the tonsillar crypts and
the glottides) display greatest susceptibility to HPV due to
the easy exposure of the basal cells, and this is also the
case with the meta-plastic epithelial area in the cervix.
Hence, it is critical to group HNSCC together as a single
entity with the consequent difficulty of comparing the
data. Recent epidemiological and molecular data have
indicated the involvement of HR HPV in a given subset of
HNSCC [14-19] (i.e. oro-pharyngeal and Waldeyer's ton-
sillar ring SCC) have been found to be significantly related
to HR HPV(especially HPV 16/18). HPV 16 was very
recently identified in tonsil-related cancers (palatine ton-
sil and at the base of the tongue) in oral exfoliated cells
together with serum antibodies against HPV 16 [20], in
non-smokers and non-drinkers, and oro-pharyngeal SCC
patients [21]. Comparing these data, no clear results for
OSCC and HR HPV have so far emerged. Various studies
report a significant association between HPV 16 and to a
lesser extent HPV 18 with OSCC [13,22-25] with respect
to the frequency of HPV in normal oral mucosa. In a
recent meta-analysis [26] of studies (1988 – 2007) on
HPV in HNSCC vs OSCC biopsies, we found that the
pooled prevalence of HPV DNA in the overall samples was
34.5%, while it was 38.1% in OSCC and 24.1% in the non
site-specific HNSCC group. Unfortunately, it was con-
firmed that only a few studies had observed a correct dis-
tinction between cancers at oral and oro-pharyngeal sites,
as recommended by the American Joint Committee on
Cancer. Finally, the misclassification of some HPV-posi-
tive oro-pharyngeal cancers, such as OSCC, could partly
explain the HPV-positivity of some "oral" cancers, thus
even diminishing the real impact of HR HPV on oro-pha-
ryngeal tumour onset [14,17].
What type of infection is a prerequisite for carcinogenesis?
As gleaned from the field of gynaecology, a persistent viral
status represents a necessary although not sufficient basis
for HPV-related lesions [7,27-31]: persistent infection
with a specific HR-HPV type must be maintained for atHead & Neck Oncology 2009, 1:8 http://www.headandneckoncology.org/content/1/1/8
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least 2 years and usually copies of the virus are found in
great numbers in cervical mucosa. However, the virus is
rarely found in oral mucosa, probably due to saliva clear-
ance. Potentially, the probability that tonsillar crypts and
the glottides will constantly harbour virions is greater
than in other mucosal oral districts, and they will be
detected with greater difficultly.
Is there any protein expression/overexpression which is 
strongly associated with HR HPV in HNC?
Our first thought regards p16 and indeed it has been
recently proposed as a surrogate marker of HPV DNA
infection for oropharyngeal cancers [32]. The results for
OSCC are less definitive [33-37], although some recent
studies performed by real-time PCR [38], tissue microar-
ray [39] and on a mouse model [40] have revealed the
ability to identify (due to an over-expression of p16) those
OSCC in which HPV infection was biologically signifi-
cant.
Does HPV positive oral cancer present a better prognosis 
and a different radio-chemo-sensitivity?
With reference to recent clinical data in the literature, HPV
has been found to be the most significant positive prog-
nostic factor in patients with oro-pharyngeal tumors, with
a 60–80% reduction in the risk of death [41]. The favour-
able outcome of HPV-induced oropharyngeal cancers
might be attributable to the absence of field cancerization
or enhanced radiation sensitivity [42]. Taking this into
consideration, the diagnosis of HPV infection should be
determined in all oropharyngeal cancers, considering its
presence as a key factor in the decision-making process of
treatment [43-45]. However, we are unable to make the
same suggestion for the OSCC. Furthermore, HPV 16 has
been positively associated with a response to chemo-radi-
ation in oro-pharyngeal cancer and with overall and dis-
ease-specific survival [46], whereas an HPV 16 positive
cell line of HNSCC was recently found to be extremely cis-
platinum-resistant [47].
How difficult is it to make a diagnosis of oral HPV 
infection?
When performing the molecular detection of HPV DNA
from oral samples, attention should be focused on the
low productivity of oral HPV infections. Indeed, studies
based on polymerase chain reaction (PCR) assay have
shown that, when compared to those from HPV-positive
cervical specimens, HPV-DNA positive oral samples from
both normal oral mucosa [13,48] and cancerous lesions
[49] produce weaker PCR products. Based on such data, it
is then essential that, in clinical and research HPV testing,
all procedures employed are highly sensitive, specific and
reliable. In addition, the aim of enhancing the standardi-
zation of the approach, in terms of the type of oral speci-
men examined, sampling method applied and HPV
molecular assay employed, should be pursued. As far as
the oral sample to be examined is concerned, both tissue
samples and superficial cells have been evaluated in liter-
ature [48,50,51]. Biopsy tissue samples can be either fro-
zen at -80°C and then minced without thawing for DNA
analysis or they can be formalin-fixed and paraffin-
embedded. Oral mucosa exfoliated cells can be obtained
either by oral brushing or rinse, and advantages and dis-
advantages have been reported for each method. Tissue
samples allow for the histo-pathological examination of
the biopsies used for the HPV test, as well as permitting
the in situ hybridization and localization of HPV DNA in
infected cells. However, the highest rate of HPV DNA is
reported in DNA from frozen tissue, but the value is much
lower for paraffin-embedded tissue samples [48]. Oral
scrapes or rinse samples, with their greater surface area of
mucosa than with biopsies, are less invasive, and HR HPV
detection in oral exfoliated cells is a reliable biomarker of
an HPV-related HN cancer risk. A drawback is that not all
patients who have HR-HPV types in oral exfoliated cells
are detected with HPV DNA in the primary tumour [50].
However, if HPV testing of oral exfoliated cells has been
selected, the use of oral rinses would appear more effi-
cient, in terms of cell yield and DNA-containing nucleated
cells, compared with the superficial brushing/scraping of
oral mucosa (by using a cotton swab, wooden spatula or
a cytobrush) [51,52]. Of the several mouthwashes tested
in the literature, commercial mouthwashes (e.g., Cepa-
col®, Listermint®) would seem more efficient than sucrose,
glucose and saline, in terms of DNA yield, quality and sta-
bility [53]. As far as HPV detection methods are con-
cerned, it has been reported that methods such as
Southern blotting and in situ hybridization should be
avoided as they lead to lower HPV rates, compared with
those obtained by using PCR assays [54,55].
As is the case with the most validated sampling proce-
dures, it should be kept in mind that there are several
other variables which may affect the efficiency and relia-
bility of HPV detection in oral samples. For instance, the
method of DNA purification also has a potentially large
impact upon the ability to detect HPV DNA by PCR ampli-
fication [56]. Additionally, considerable differences exist
regarding the use of different PCR primers. In the majority
of the PCR-based HPV detection systems, a broad spec-
trum of HPV types is amplified by consensus primers, fol-
lowed by detection with type-specific probes. The
consensus primers may be either degenerate (as in the
MY09/11 systems), or they may contain mismatches (as
in the GP5+/6+ system), or they may contain inosine res-
idues at ambiguous base positions (as in the SPF primers),
or sets of overlapping primers (as in the PGMY primers).
These methods have different analytical and clinical char-
acteristics [57], and every method has its strengths and
weakness. Although difficult to achieve, standardizationHead & Neck Oncology 2009, 1:8 http://www.headandneckoncology.org/content/1/1/8
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and the use of validated procedures for HPV DNA is para-
mount in assisting physicians to provide more effective
treatment and more efficient screening for patients.
What is the most common route of oral HPV transmission?
Even though modes of HPV transmission in the head and
neck mucosal districts have not been fully resolved, theo-
ries have proposed multiple pathways for HPV transmis-
sion, including perinatal transmission, auto-infection
from oral-genital contact by hand and sexual transmission
by oral-genital contact. The perinatal transmission of HPV
to neonates at birth has been detected in several studies
which have demonstrated that recurrent respiratory papil-
lomatosis is associated with the perinatal transmission of
HPV. While the possibility of auto-infection among
women with cervical HPV infection is still a matter of
debate [52,58-60], oral sex, including fellatio and cunni-
lingus, has being hypothesized as being the main mode of
transit for oral HPV infection. Recently, HPV was detected
more commonly in biopsy specimens from cancer
patients with more than one sexual partner and from
those who practiced oral sex than in biopsy specimens
from those who did not engage in oral sex, thereby con-
firming the possibility of oral transmission [61]. How-
ever, mouth-to-mouth transmission, for example through
kissing, still remains possible and it should not be
excluded as a route of oral HPV transmission. Since the
onset of the HIV epidemic, an increase in oral sex among
teenagers and young adults has been observed, probably
because this is thought to represent a form of safe sex.
However, oral sex is not free of risk and it can result in
HPV-related cancer. Public education is of paramount
importance: there is a need to disseminate these findings
and to place them in context. Even though the transmis-
sion of genital HPV infection primarily occurs via sexual
contact, HPV-related diseases such as condyloma acumi-
nata and laryngeal papillomas occur in neonates and chil-
dren [62], suggesting additional modes of viral
transmission such as perinatal infection during the pas-
sage through an infected birth canal [63] and in utero, as a
transplacental or ascending infection [64,65]. Caesarean
deliveries do not protect neonates against HPV [66] and
HPV infection may be associated with adverse pregnancy
outcomes, including spontaneous preterm delivery [67].
Is HPV prevention possible and useful?
Although the use of condoms has proven efficient in the
prevention of most sexually-transmitted infections, the
effectiveness for prevention against HPV infection is not
as clear, and a significant variability (from 0% to 80%) in
the condom protection of HPV infection has been
reported [68]. Alternatively, HPV infection could be pre-
vented by the use of type-specific vaccines. In recent years,
two HPV vaccines have been developed and are they avail-
able for primary vaccination in the European Union: a
vaccine against HPV-16 and HPV-18 (Cervarix, produced
by GlaxoSmithKline), which is administered in three
doses (time 0, 1, and 6 months), and a quadrivalent vac-
cine against HPV-16, HPV-18, HPV-6 and HPV-11 (pro-
duced by Merck and distributed in Europe by Sanofi
Pasteur MSD as Gardasil), which is administered in three
doses (time 0, 2, and 6 months). The impressive range of
protection, ranging from 86% to 100%, of the HPV vac-
cines has been recently reported [69,70]. The bivalent vac-
cine is advised for a reduction of precancerous cervical
lesions and cancer incidence. In addition to cervical can-
cer prevention, the quadrivalent vaccine is advised for a
reduction in genital condylomas. It is thought that these
HPV vaccines could have broader implications, also for
other HPV-related cancer in both women and men,
thereby preventing oral as well as genital infections. This
has prompted many researchers to advocate vaccinating
boys as well as girls, with the bivalent vaccine to prevent
HNC and by the tetravalent vaccine to additionally pre-
vent oral condilomatosis. Thus, the question is "Can
oropharyngeal cancer now be placed in the category of virally-
mediated cancers?", like, for instance, HPV-related cervical,
anal, vulvar, and penile cancers, or the Epstein Barr virus-
associated nasopharyngeal cancers. Whilst it is premature
to imagine an HPV vaccine which could protect women
and men against HNC, the possibility that various oral,
oro-pharyngeal, and laryngeal cancers might be prevented
by HPV vaccination is certainly a hope, and this would
bring forth significant implications from a public health
perspective.
Beyond the vaccines, the potentiality of gene therapy
HPV vaccines should eventually reduce the impact of
these viruses on human health. However, vaccines may
not be useful for the treatment of existing disease, and it is
necessary to develop effective therapies targeting those
individuals who are already infected or are currently
excluded from the first phase of a prophylactic vaccina-
tion program. Given the strong relationship between the
expression of HPV E6 and E7 and cervical cancer carcino-
genesis, many approaches have been directed against
these oncogenes, for example, gene therapy for HPV-pos-
itive cervical cancers [71]. The different methods also
include the treatment of cervical cancer with E6 short
interfering RNA, the use of antisense RNA to E7 and E6
genes either alone or together, and the use of mutated E2
protein that acts as a cancer cell-specific inducer of apop-
tosis [72-74]. In in vitro studies on antisense HPV RNA
transcripts, the transcripts of the E6 and E7 genes of HPV
type 16 were introduced (via a recombinant adenoviral
vector,  e.g., Ad5CMV-HPV 16 AS) into human cervical
cancer cells harbouring HPV 16; the effects of expression
of these genes on cell and tumour growth were then ana-
lysed. It was found that, when E6 and E7 protein expres-
sion is suppressed, p53 and Rb protein expressionHead & Neck Oncology 2009, 1:8 http://www.headandneckoncology.org/content/1/1/8
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increase, the Ad5CMV-HPV 16 AS-infected cells undergo
apoptosis, and cell growth and tumourigenicity are greatly
suppressed. However, even though gene therapy may
prove to be beneficial in the treatment of cervical cancer
and other HPV-induced diseases, a further understanding
of the viral life cycle and the mechanisms underlying
HPV-induced oncogenesis is necessary before this method
could be employed for clinical use in humans.
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